Milestone Pharmaceuticals, a Montreal, Canada-based late-stage biopharmaceutical company developing interventions for tachycardias, completed an $80m equity financing.
The round was led by RTW Investments, with participation from Venrock Healthcare Capital Partners, Boxer Capital, Novo Holdings, Forbion, funds managed by Tekla Capital Management, Domain Associates, BDC Capital, Pappas Capital, GO Capital, and Fonds de solidarité FTQ.
Led by Joseph Oliveto, President and Chief Executive Officer, Milestone Pharmaceuticals is a late-stage biopharmaceutical company focused on developing an investigational new drug intended to provide rapid-onset and short-acting treatment of paroxysmal supraventricular tachycardia (PSVT) episodes and other episodic conditions.
The company intends to use the funds to execute on ongoing Phase 3 clinical program and select commercial pre-launch activities of etripamil, an investigational new drug for the treatment of paroxysmal supraventricular tachycardia (PSVT), and expand its pipeline, including studies of etripamil in other cardiovascular indications where calcium channel blockers have demonstrated utility.
Milestone has a U.S. subsidiary in Charlotte, N.C.